Role of Complexed PSA in the Early Detection of Prostate Cancer

Prostate cancer is a clinically significant health care problem in the United States. Total prostate specific antigen (tPSA) is widely used to detect prostate cancer with a significant increase in the incidence of organ-confined disease at the time of diagnosis. The limitations of tPSA are low specificity and positive predictive value. Numerous attempts to enhance PSA's performance based on prostate volume, patient age, patient race, and PSA velocity have shown little clinical improvement. Percent free PSA has proven to be somewhat improved but still limited. Recently, the complexed PSA (cPSA) assay was developed and multisite institutional studies have shown that cPSA has improved specificity over tPSA. Complexed PSA can replace tPSA as a first screening test.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Yoshio Naya, MD, PhD, Department of Urology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kyoto, Japan, 602-8566. E-mail: yoshionaya@hotmail.com
  • 1

    JemalAMurrayTSamuelsA. Cancer statistics, 2003. CA Cancer J Clin2003;53:526.

  • 2

    CatalonaWJSmithDSRatliffTL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med1991;324:11561161.

    • Search Google Scholar
    • Export Citation
  • 3

    BabaianRJKojimaMRamirezEI. Comparative analysis of prostate specific antigen and its indexes in the detection of prostate cancer. J Urol1996;156:432437.

    • Search Google Scholar
    • Export Citation
  • 4

    NalderRBHumphreyPASmithDS. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostatic specific antigen levels. J Urol1995;154:407413.

    • Search Google Scholar
    • Export Citation
  • 5

    DjavanBZlottaARByttebierG. Prostate specific antigen density of the transition zone for early detection of prostate cancer. J Urol1998;160:411418.

    • Search Google Scholar
    • Export Citation
  • 6

    MaedaHAraiYIshitoyaS. Prostate specific antigen adjusted for the transition zone volume as an indicator of prostate cancer. J Urol1997;158:21932196.

    • Search Google Scholar
    • Export Citation
  • 7

    DeAntoniEPCrawfordEDOesterlingJE. Age- and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology1996;48:234239.

    • Search Google Scholar
    • Export Citation
  • 8

    CatalonaWJPartinAWSlawinKM. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. A prospective multicenter clinical trial. JAMA1998;279:15421547.

    • Search Google Scholar
    • Export Citation
  • 9

    CatalonaWJPartinAWFinlayJA. Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when PSA levels are 2.51 to 4 ng/ml and digital rectal examination is not suspicious for prostate cancer: an alternative model. Urology1999;54:220224.

    • Search Google Scholar
    • Export Citation
  • 10

    DjavanBZlottaAKratzikC. PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. Urology1999;54:517522.

    • Search Google Scholar
    • Export Citation
  • 11

    JungKStephanCElgetiU. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer?Int J Cancer2001;93:759765.

    • Search Google Scholar
    • Export Citation
  • 12

    RoehlKAAntenorJVCatalonaWJ. Robustness of free prostate specific antigen measurements to reduce unnecessary biopsies in the 2.6 to 4.0 ng/mL range. J Urol2002;168:922925.

    • Search Google Scholar
    • Export Citation
  • 13

    StenmanUHLeinonenJAlfthanH. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of men with prostatic cancer: Assay of the complex improves clinical sensitivity for cancer. Cancer Res1991;51:222226.

    • Search Google Scholar
    • Export Citation
  • 14

    ChristenssonABjorkTNilssonO. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol1993;150:100105.

    • Search Google Scholar
    • Export Citation
  • 15

    LiljaHChristenssonADahlenU. Prostate specific antigen (PSA) in human serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem1991;37:16181625.

    • Search Google Scholar
    • Export Citation
  • 16

    AllardWJZhouZYeungKK. Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. Clin Chem1998;44:12161223.

    • Search Google Scholar
    • Export Citation
  • 17

    BrawerMKMeyerGELetranJL. Measurement of complexed PSA improves specificity for early detection of prostate cancer. Urology1998;52:372378.

    • Search Google Scholar
    • Export Citation
  • 18

    BrawerMKMeyerGELetranJL. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol2000;163:14761480.

    • Search Google Scholar
    • Export Citation
  • 19

    MitchellIDCroalBLDickieA. A prospective study to evaluate the role of complexed prostate specific antigen ratio for the diagnosis of prostate cancer. J Urol2001;165:15491553.

    • Search Google Scholar
    • Export Citation
  • 20

    MorrisDLDillonPWVeryDL. Bayer Immuno 1 PSA Assay: an automated, ultrasensitive method to quantitate total PSA in serum. J Clin Lab Anal1998;12:6574.

    • Search Google Scholar
    • Export Citation
  • 21

    OkiharaKUkimuraONakamuraT. Can complexed prostate specific antigen enhance prostate cancer detection in Japanese men?Eur Urol (in press).

    • Search Google Scholar
    • Export Citation
  • 22

    IanWIrajBFrankM. Acridinium esters as high-specific-activity labels in immunoassay. Clin Chem1983;29:14741479.

  • 23

    OkegawaTNodaHNutaharaK. Comparison of two investigative assays for the complexed prostate specific-antigen in total prostate-specific antigen between 4.1 and 10.0 ng/mL. Urology2000;55:700704.

    • Search Google Scholar
    • Export Citation
  • 24

    StameyTAYemotoCE. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume. J Urol2000;163:119126.

    • Search Google Scholar
    • Export Citation
  • 25

    OkiharaKCheliCDPartinAW. Comparative analysis of complexed prostate specific antigen, free prostate specific antigen and their ratio in detecting prostate cancer. J Urol2002;167:20172024.

    • Search Google Scholar
    • Export Citation
  • 26

    CatalonaWJSmithDSOrnsteinDK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/ml and benign prostate examination. Enhancement of specificity with free PSA measurements. JAMA1997;277:14521455.

    • Search Google Scholar
    • Export Citation
  • 27

    SmithDSCarvalhalGFMagerDE. Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men. J Urol1998;160:17341738.

    • Search Google Scholar
    • Export Citation
  • 28

    BabaianRJJohnstonDANaccaratoW. The incidence of prostate cancer in screening population with a serum prostate specific antigen between 2.5 and 4.0 ng/ml: relation to biopsy strategy. J Urol2001;165:757760.

    • Search Google Scholar
    • Export Citation
  • 29

    OkiharaKFristcheHAAyalaA. Can complexed prostate specific antigen and prostatic volume enhance prostate cancer detection in men with total prostate specific antigen between 2.5 and 4.0 ng/ml. J Urol2001;165:19301936.

    • Search Google Scholar
    • Export Citation
  • 30

    HorningerWCheliCDBabaianRJ. Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. Urology2002;60(Suppl 4a):3135.

    • Search Google Scholar
    • Export Citation
  • 31

    NayaYStameyTACheliCD. Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?Urology2002;60(Suppl 4a):3641.

    • Search Google Scholar
    • Export Citation
  • 32

    PartinAWBrawerMKBartchG. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial. J Urol2003;170:17871791.

    • Search Google Scholar
    • Export Citation
  • 33

    DjavanBRemziMZlottaAR. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. Urology2002;60(Suppl 4a):49.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 341 326 41
PDF Downloads 226 220 45
EPUB Downloads 0 0 0